Skip to main content
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: Exp Neurol. 2007 Aug 22;208(1):110–119. doi: 10.1016/j.expneurol.2007.07.021

Table 1.

 
 Property
 Timing (days of levodopa)
WIN 55,212-2 Cannabinoid agonist From day 9 to 12
URB597 FAAH inhibitor From day 9 to 12
AM251 CB1 antagonist Day 12
SR141617A CB1 antagonist Day 12
Capsazepine TRPV1 antagonist From day 9 to 12*
*

in combination with URB597

HHS Vulnerability Disclosure